There could be a potential anti-carcinogenetic mechanism for FGF21 via a negative feedback loop on the TLR4-IL-17A axis in the liver; this hypothesis was supported by the findings in which high expression of FGF21 and low expression of IL-17A were closely correlated with better prognosis in the HCC patients. The gene discussed is IL17A; the disease is hepatocellular carcinoma.